(Reuters) – A committee of the European healthcare regulator urged researchers to prioritize larger studies into potential treatments for COVID-19, as they are most likely to generate conclusive data.
Large multi-centre, multi-arm clinical trials must include all EU countries to enable faster development of a treatment for the disease caused by the coronavirus, the European Medicines Agency’s human medicines committee said on Thursday. (http://bit.ly/33uCHEL)
(Reporting by Pushkala Aripaka in Bengaluru, Editing by Sherry Jacob-Phillips)
